Matthew L. Posard, Director at Talis Biomedical Corp (TLIS), bought 62,500 shares at $16.00 ($1.0M) on 2021-02-17, disclosed to the SEC on 2021-02-19.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| Filing → |
| HALO | SELL | 2024-08-14 | $2.3M | — | Filing → |
| HALO | SELL | 2024-06-13 | $1.0M | — | Filing → |
| HALO | SELL | 2022-12-06 | $1.7M | — | Filing → |